Therapeutic Uses
Anti-Cancer / Oncology
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-di(methyl-d3)-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-N-methylbenzamide
Application Notes
Useful research chemical for a range of applications
Purity by HPLC
Not less than 90%
Hazard Compound
No -Refer MSDS for accurate information
Enzalutamide-d6 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Enzalutamide-d6 usage and description
Enzalutamide D6 is a deuterated derivative of Enzalutamide, a non-steroidal antiandrogen drug. Enzalutamide D6 is used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) in men who have received prior chemotherapy. It works by blocking the binding of androgens (male hormones) to the androgen receptor, which slows the growth and spread of prostate cancer cells.
Enzalutamide D6 is an isotopically labeled compound, meaning that six deuterium atoms have been substituted for six hydrogen atoms in the molecular structure. This labeling allows for easy tracking and analysis of the compound in biological systems. It has a molecular formula of C21H16D6F4N4O2 and a molecular weight of 446.51 g/mol.
The recommended dosage of Enzalutamide D6 is 160 mg taken orally once daily. It is important to follow the prescribed dosage and administration instructions carefully, as overdose or improper use can lead to unwanted side effects such as fatigue, headache, nausea, and high blood pressure.
Enzalutamide D6 is metabolized primarily by the liver and excreted in the feces. It has a half-life of approximately 5-8 days, meaning that it takes this amount of time for half of the drug to be eliminated from the body. Enzalutamide D6 has been extensively studied in clinical trials and has shown promising results in the treatment of mCRPC, offering improved survival rates and quality of life for patients.
